Originally published by our sister publication, Pain Medicine News.
The FDA gave Quell (NeuroMetrix), a wearable neurostimulation device, a breakthrough designation for reducing moderate to severe chemotherapy-induced peripheral neuropathy (CIPN) that persists for six months or more after the end of chemotherapy.